Wave Life Sciences Ltd. (WVE)
Largest Insider Buys in Sector
WVE Stock Price History Chart
WVE Stock Performance
About Wave Life Sciences Ltd.
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin …
Insider Activity of Wave Life Sciences Ltd.
Over the last 12 months, insiders at Wave Life Sciences Ltd. have bought $43.84M and sold $6.05M worth of Wave Life Sciences Ltd. stock.
On average, over the past 5 years, insiders at Wave Life Sciences Ltd. have bought $43.84M and sold $2.15M worth of stock each year.
Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $125M. GSK plc (10 percent owner) — $38.84M.
The last purchase of 2,791,930 shares for transaction amount of $22.34M was made by GSK plc (10 percent owner) on 2024‑09‑27.
List of Insider Buy and Sell Transactions, Wave Life Sciences Ltd.
| 2024-11-15 | Sale | President and CEO | 51,234 0.0315% | $14.32 | $733,671 | +4.65% | ||
| 2024-11-08 | Sale | See Remarks | 36,000 0.0228% | $16.00 | $576,000 | -8.64% | ||
| 2024-10-16 | Sale | President and CEO | 90,474 0.1357% | $15.00 | $1.36M | -1.95% | ||
| 2024-10-16 | Sale | See Remarks | 208,836 0.2854% | $13.67 | $2.86M | -1.95% | ||
| 2024-09-27 | 10 percent owner | 2.79M 2.2327% | $8.00 | $22.34M | +66.59% | |||
| 2024-09-25 | Sale | Chief Financial Officer | 17,146 0.0232% | $9.00 | $154,314 | 0.00% | ||
| 2024-08-21 | Sale | President and CEO | 48,366 0.0383% | $5.78 | $279,555 | +41.79% | ||
| 2024-04-03 | Sale | Chief Financial Officer | 15,630 0.0133% | $6.17 | $96,421 | 0.00% | ||
| 2023-12-11 | 1M 1.2134% | $5.00 | $5M | +38.73% | ||||
| 2023-12-07 | 10 percent owner | 3.3M 3.4922% | $5.00 | $16.5M | +20.94% | |||
| 2023-08-23 | Sale | Chief Financial Officer | 37,062 0.0365% | $4.75 | $176,119 | +10.31% | ||
| 2023-02-16 | Sale | President and CEO | 29,400 0.0251% | $4.04 | $118,776 | -5.01% | ||
| 2023-02-16 | Sale | See Remarks | 10,249 0.0087% | $4.03 | $41,303 | -5.01% | ||
| 2023-02-16 | Sale | Chief Financial Officer | 9,729 0.0083% | $4.04 | $39,305 | -5.01% | ||
| 2023-02-16 | Sale | See Remarks | 10,258 0.0087% | $4.03 | $41,340 | -5.01% | ||
| 2022-05-04 | Sale | President and CEO | 33,501 0.0447% | $1.72 | $57,622 | +106.19% | ||
| 2022-05-04 | Sale | See Remarks | 16,714 0.0223% | $1.72 | $28,748 | +106.19% | ||
| 2022-05-04 | Sale | See Remarks | 16,714 0.0223% | $1.72 | $28,748 | +106.19% | ||
| 2022-05-04 | Sale | See Remarks | 10,867 0.0145% | $1.72 | $18,691 | +106.19% | ||
| 2022-05-04 | Sale | Chief Financial Officer | 5,021 0.0067% | $1.72 | $8,636 | +106.19% |
Insider Historical Profitability
| RA CAPITAL MANAGEMENT, L.P. | 18202009 11.9342% | $14.25 | 6 | 0 | +47.04% | |
| GSK plc | 10 percent owner | 16775691 10.999% | $14.25 | 2 | 0 | |
| Tanaka Masaharu | 2774118 1.8189% | $14.25 | 2 | 3 | +2.01% | |
| TAKANASHI KEN | 1984130 1.3009% | $14.25 | 2 | 0 | +2.01% |
Institutional Investor Ownership
| RA Capital Management, L.P. | $112.31M | 14.86 | 18.2M | 0% | +$0 | 0.11 | |
| Maverick Capital Ltd | $47.44M | 6.28 | 7.69M | -8.99% | -$4.69M | 0.92 | |
| M28 Capital Management Lp | $43.19M | 5.72 | 7M | -5.06% | -$2.3M | 31.91 | |
| BlackRock | $39.34M | 5.21 | 6.38M | +18.8% | +$6.23M | <0.01 | |
| 683 Capital Management Llc | $33.01M | 4.37 | 5.35M | -4.46% | -$1.54M | 3.58 |